{"id":31622,"date":"2025-04-11T16:50:07","date_gmt":"2025-04-11T08:50:07","guid":{"rendered":"https:\/\/flcube.com\/?p=31622"},"modified":"2025-04-11T16:50:08","modified_gmt":"2025-04-11T08:50:08","slug":"pierre-fabre-and-redridge-bio-partner-on-biparatopic-antibody-development-for-precision-oncology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31622","title":{"rendered":"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology"},"content":{"rendered":"\n

France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG to identify and develop biparatopic antibody (BPA) drug candidates targeting multiple therapeutic areas. The collaboration, aligned with Pierre Fabre’s innovation strategy, will focus on precision oncology, dermatology, and rare diseases, leveraging the complementary strengths of both companies.<\/p>\n\n\n\n

Partnership Structure and Responsibilities<\/strong>
Under the agreement, Red Ridge Bio will be responsible for engineering, screening, and characterizing BPAs against an undisclosed portfolio of jointly nominated targets. Pierre Fabre will support the advancement of two co-development programs through clinical development. Red Ridge Bio will hold exclusive commercial rights in the United States, Canada, and Japan for these programs, while Pierre Fabre will own exclusive rights for the rest of the world. Additionally, Pierre Fabre will acquire exclusive worldwide rights for a third program following a preclinical hand-off from Red Ridge Bio.<\/p>\n\n\n\n

Financial Terms and Investment Support<\/strong>
The financial terms of the agreement include an undisclosed upfront payment, milestone payments, and future sales royalties. Pierre Fabre will also fund research payments for its worldwide program and share R&D costs for the co-development programs. In a further show of support, Pierre Fabre will back Red Ridge Bio in its upcoming Series A financing round.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG…<\/p>\n","protected":false},"author":1,"featured_media":31624,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[28,2905,3849],"class_list":["post-31622","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-multi-specific-antibodies","tag-pierre-fabre","tag-redridge-bio"],"yoast_head":"\nPierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"France's Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG to identify and develop biparatopic antibody (BPA) drug candidates targeting multiple therapeutic areas. The collaboration, aligned with Pierre Fabre's innovation strategy, will focus on precision oncology, dermatology, and rare diseases, leveraging the complementary strengths of both companies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31622\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology\" \/>\n<meta property=\"og:description\" content=\"France's Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG to identify and develop biparatopic antibody (BPA) drug candidates targeting multiple therapeutic areas. The collaboration, aligned with Pierre Fabre's innovation strategy, will focus on precision oncology, dermatology, and rare diseases, leveraging the complementary strengths of both companies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31622\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-11T08:50:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-11T08:50:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1111-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology\",\"datePublished\":\"2025-04-11T08:50:07+00:00\",\"dateModified\":\"2025-04-11T08:50:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1111-png.webp\",\"keywords\":[\"Multi-specific antibodies\",\"Pierre Fabre\",\"RedRidge Bio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31622#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31622\",\"name\":\"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1111-png.webp\",\"datePublished\":\"2025-04-11T08:50:07+00:00\",\"dateModified\":\"2025-04-11T08:50:08+00:00\",\"description\":\"France's Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG to identify and develop biparatopic antibody (BPA) drug candidates targeting multiple therapeutic areas. The collaboration, aligned with Pierre Fabre's innovation strategy, will focus on precision oncology, dermatology, and rare diseases, leveraging the complementary strengths of both companies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31622\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1111-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1111-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pierre Fabre and Red Ridge Bio Partner on Biparatopic Antibody Development for Precision Oncology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31622#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology - Insight, China's Pharmaceutical Industry","description":"France's Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG to identify and develop biparatopic antibody (BPA) drug candidates targeting multiple therapeutic areas. The collaboration, aligned with Pierre Fabre's innovation strategy, will focus on precision oncology, dermatology, and rare diseases, leveraging the complementary strengths of both companies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31622","og_locale":"en_US","og_type":"article","og_title":"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology","og_description":"France's Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG to identify and develop biparatopic antibody (BPA) drug candidates targeting multiple therapeutic areas. The collaboration, aligned with Pierre Fabre's innovation strategy, will focus on precision oncology, dermatology, and rare diseases, leveraging the complementary strengths of both companies.","og_url":"https:\/\/flcube.com\/?p=31622","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-11T08:50:07+00:00","article_modified_time":"2025-04-11T08:50:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1111-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31622#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31622"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology","datePublished":"2025-04-11T08:50:07+00:00","dateModified":"2025-04-11T08:50:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31622"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31622#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1111-png.webp","keywords":["Multi-specific antibodies","Pierre Fabre","RedRidge Bio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31622#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31622","url":"https:\/\/flcube.com\/?p=31622","name":"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31622#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31622#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1111-png.webp","datePublished":"2025-04-11T08:50:07+00:00","dateModified":"2025-04-11T08:50:08+00:00","description":"France's Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG to identify and develop biparatopic antibody (BPA) drug candidates targeting multiple therapeutic areas. The collaboration, aligned with Pierre Fabre's innovation strategy, will focus on precision oncology, dermatology, and rare diseases, leveraging the complementary strengths of both companies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31622#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31622"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31622#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1111-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1111-png.webp","width":1080,"height":608,"caption":"Pierre Fabre and Red Ridge Bio Partner on Biparatopic Antibody Development for Precision Oncology"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31622#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1111-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31622"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31622\/revisions"}],"predecessor-version":[{"id":31625,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31622\/revisions\/31625"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31624"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}